Engineering CAR-T Cells for Next-Generation Cancer Therapy

Adachi, 2018, IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor, Nat. Biotechnol., 36, 346, 10.1038/nbt.4086

Avanzi, 2018, Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system, Cell Rep., 23, 2130, 10.1016/j.celrep.2018.04.051

Awong, 2011, Human CD8 T cells generated in vitro from hematopoietic stem cells are functionally mature, BMC Immunol., 12, 22, 10.1186/1471-2172-12-22

Bachmann, 2019, The UniCAR system: a modular CAR T cell approach to improve the safety of CAR T cells, Immunol. Lett., 211, 13, 10.1016/j.imlet.2019.05.003

Boice, 2016, Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells, Cell, 167, 405, 10.1016/j.cell.2016.08.032

Cartellieri, 2016, Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts, Blood Cancer J., 6, e458, 10.1038/bcj.2016.61

Carty, 2018, The loss of TET2 promotes CD8+ T cell memory differentiation, J. Immunol., 200, 82, 10.4049/jimmunol.1700559

Caruana, 2015, Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes, Nat. Med., 21, 524, 10.1038/nm.3833

Casucci, 2018, Extracellular NGFR spacers allow efficient tracking and enrichment of fully functional CAR-T cells co-expressing a suicide gene, Front. Immunol., 9, 507, 10.3389/fimmu.2018.00507

Cella, 1996, Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation, J. Exp. Med., 184, 747, 10.1084/jem.184.2.747

Chang, 2018, Rewiring T-cell responses to soluble factors with chimeric antigen receptors, Nat. Chem. Biol., 14, 317, 10.1038/nchembio.2565

Chen, 2013, Molecular mechanisms of T cell co-stimulation and co-inhibition, Nat. Rev. Immunol., 13, 227, 10.1038/nri3405

Chen, 2017, CAR T-cell intrinsic PD-1 checkpoint blockade: a two-in-one approach for solid tumor immunotherapy, Oncoimmunology, 6, e1273302, 10.1080/2162402X.2016.1273302

Chen, 2015, Efficient gene editing in primary human T cells, Trends Immunol., 36, 667, 10.1016/j.it.2015.09.001

Cherkassky, 2016, Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition, J. Clin. Invest., 126, 3130, 10.1172/JCI83092

Chmielewski, 2017, CAR T cells releasing IL-18 convert to T-Bet(high) FoxO1(low) effectors that exhibit augmented activity against advanced solid tumors, Cell Rep., 21, 3205, 10.1016/j.celrep.2017.11.063

Chmielewski, 2014, Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma, Immunol. Rev., 257, 83, 10.1111/imr.12125

Cho, 2018, Universal chimeric antigen receptors for multiplexed and logical control of T cell responses, Cell, 173, 1426, 10.1016/j.cell.2018.03.038

Choi, 2019, CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity, Nat. Biotechnol., 37, 1049, 10.1038/s41587-019-0192-1

Chu, 2014, CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma, Leukemia, 28, 917, 10.1038/leu.2013.279

Collinson-Pautz, 2019, Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies, Leukemia, 33, 2195, 10.1038/s41375-019-0417-9

Curran, 2015, Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression, Mol. Ther., 23, 769, 10.1038/mt.2015.4

Di Stasi, 2009, T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model, Blood, 113, 6392, 10.1182/blood-2009-03-209650

Ede, 2016, Quantitative analyses of core promoters enable precise engineering of regulated gene expression in mammalian cells, ACS Synth. Biol., 5, 395, 10.1021/acssynbio.5b00266

Eil, 2016, Ionic immune suppression within the tumour microenvironment limits T cell effector function, Nature, 537, 539, 10.1038/nature19364

Eshhar, 1993, Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors, Proc. Natl. Acad. Sci. U S A, 90, 720, 10.1073/pnas.90.2.720

Eyquem, 2017, Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection, Nature, 543, 113, 10.1038/nature21405

Fedorov, 2013, PD-1– and CTLA-4–based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses, Sci. Transl. Med., 5, 2, 10.1126/scitranslmed.3006597

Fraietta, 2018, Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells, Nature, 558, 307, 10.1038/s41586-018-0178-z

Fry, 2018, CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy, Nat. Med., 24, 20, 10.1038/nm.4441

Fu, 2019, CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity, Nat. Commun., 10, 4355, 10.1038/s41467-019-12321-3

Gajewski, 2013, Innate and adaptive immune cells in the tumor microenvironment, Nat. Immunol., 14, 1014, 10.1038/ni.2703

Geiger, 2016, L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity, Cell, 167, 829, 10.1016/j.cell.2016.09.031

Genßler, 2016, Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival, Oncoimmunology, 5, e1119354, 10.1080/2162402X.2015.1119354

Georgiadis, 2018, Long terminal repeat CRISPR-CAR-coupled “universal" T cells mediate potent anti-leukemic effects, Mol. Ther., 26, 1215, 10.1016/j.ymthe.2018.02.025

Griffioen, 2009, Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy, Haematologica, 94, 1316, 10.3324/haematol.2008.001677

Grosser, 2019, Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors, Cancer Cell, 36, 471, 10.1016/j.ccell.2019.09.006

Guedan, 2018, Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation, JCI Insight, 3, e96976, 10.1172/jci.insight.96976

Han, 2017, Masked chimeric antigen receptor for tumor-specific activation, Mol. Ther., 25, 274, 10.1016/j.ymthe.2016.10.011

Haynes, 2002, Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors, Blood, 100, 3155, 10.1182/blood-2002-04-1041

Hegde, 2016, Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape, J. Clin. Invest., 126, 3036, 10.1172/JCI83416

Herzig, 2019, Attacking latent HIV with convertibleCAR-T cells, a highly adaptable killing platform, Cell, 179, 880, 10.1016/j.cell.2019.10.002

Ho, 2017, Modularly constructed synthetic granzyme B molecule enables interrogation of intracellular proteases for targeted cytotoxicity, ACS Synth. Biol., 6, 1484, 10.1021/acssynbio.6b00392

Ho, 2015, Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses, Cell, 162, 1217, 10.1016/j.cell.2015.08.012

Hombach, 2012, OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells, Oncoimmunology, 1, 458, 10.4161/onci.19855

Hoogi, 2019, A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function, J Immunother Cancer, 7, 243, 10.1186/s40425-019-0721-y

Hou, 2018, TGF-β–responsive CAR-T cells promote anti-tumor immune function, Bioeng. Transl. Med., 3, 75, 10.1002/btm2.10097

Hoyos, 2010, Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety, Leukemia, 24, 1160, 10.1038/leu.2010.75

Hu, 2017, Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18, Cell Rep., 20, 3025, 10.1016/j.celrep.2017.09.002

Hurton, 2016, Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells, Proc. Natl. Acad. Sci. U S A, 113, E7788, 10.1073/pnas.1610544113

Imai, 2004, Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia, Leukemia, 18, 676, 10.1038/sj.leu.2403302

Jin, 2019, CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors, Nat. Commun., 10, 4016, 10.1038/s41467-019-11869-4

Juillerat, 2017, An oxygen sensitive self-decision making engineered CAR T-cell, Sci. Rep., 7, 39833, 10.1038/srep39833

Juillerat, 2019, Modulation of chimeric antigen receptor surface expression by a small molecule switch, BMC Biotechnol., 19, 44, 10.1186/s12896-019-0537-3

Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci. Transl Med., 3, 95ra73, 10.1126/scitranslmed.3002842

Kawalekar, 2016, Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells, Immunity, 44, 380, 10.1016/j.immuni.2016.01.021

Klinchinsky, 2020, Human chimeric antigen receptor macrophages for cancer immunotherapy, Nat. Biotechnol.

Kloss, 2013, Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells, Nat. Biotechnol., 31, 71, 10.1038/nbt.2459

Kloss, 2018, Dominant-negative TGF-beta receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication, Mol. Ther., 26, 1855, 10.1016/j.ymthe.2018.05.003

Kotch, 2019, Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome, Expert Rev. Clin. Immunol., 15, 813, 10.1080/1744666X.2019.1629904

Kuhn, 2019, CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response, Cancer Cell, 35, 473, 10.1016/j.ccell.2019.02.006

Kumari, 2016, Role of interleukin-6 in cancer progression and therapeutic resistance, Tumour Biol., 37, 11553, 10.1007/s13277-016-5098-7

Labanieh, 2018, Programming CAR-T cells to kill cancer, Nat. Biomed. Eng., 2, 377, 10.1038/s41551-018-0235-9

Lai, 2020, Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity, Nat. Immunol., 21, 914, 10.1038/s41590-020-0676-7

Lee, 2014, Current concepts in the diagnosis and management of cytokine release syndrome, Blood, 124, 188, 10.1182/blood-2014-05-552729

Lee, 2019, ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells, Biol. Blood Marrow Transpl., 25, 625, 10.1016/j.bbmt.2018.12.758

Lee, 2019, Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters, Nat. Commun., 10, 2681, 10.1038/s41467-019-10565-7

Leen, 2014, Reversal of tumor immune inhibition using a chimeric cytokine receptor, Mol. Ther., 22, 1211, 10.1038/mt.2014.47

Li, 2018, Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity, Cell Stem Cell, 23, 181, 10.1016/j.stem.2018.06.002

Ligtenberg, 2016, Coexpressed catalase protects chimeric antigen receptor-redirected T cells as well as bystander cells from oxidative stress-induced loss of antitumor activity, J. Immunol., 196, 759, 10.4049/jimmunol.1401710

Liu, 2017, CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells, Cell Res., 27, 154, 10.1038/cr.2016.142

Liu, 2019, Armored inducible expression of IL-12 enhances antitumor activity of glypican-3-targeted chimeric antigen receptor-engineered T cells in hepatocellular carcinoma, J. Immunol., 203, 198, 10.4049/jimmunol.1800033

Lo, 2008, Harnessing the tumour-derived cytokine, CSF-1, to co-stimulate T-cell growth and activation, Mol. Immunol., 45, 1276, 10.1016/j.molimm.2007.09.010

Long, 2015, 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors, Nat. Med., 21, 581, 10.1038/nm.3838

MacLeod, 2017, Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells, Mol. Ther., 25, 949, 10.1016/j.ymthe.2017.02.005

Marin, 2012, Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells, Hum. Gene Ther. Methods, 23, 376, 10.1089/hgtb.2012.050

Markley, 2010, IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice, Blood, 115, 3508, 10.1182/blood-2009-09-241398

Mestermann, 2019, The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells, Sci. Transl. Med., 11, eaau5907, 10.1126/scitranslmed.aau5907

Montel-Hagen, 2019, Organoid-induced differentiation of conventional T cells from human pluripotent stem cells, Cell Stem Cell, 24, 376, 10.1016/j.stem.2018.12.011

Morgan, 2018, Engineering CAR-T cells for improved function against solid tumors, Front. Immunol., 9, 2493, 10.3389/fimmu.2018.02493

Moritz, 1994, Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells, Proc. Natl. Acad. Sci. U S A, 91, 4318, 10.1073/pnas.91.10.4318

Newick, 2017, CAR T cell therapy for solid tumors, Annu. Rev. Med., 68, 139, 10.1146/annurev-med-062315-120245

Oelkrug, 2014, Enhancement of T cell recruitment and infiltration into tumours, Clin. Exp. Immunol., 178, 1, 10.1111/cei.12382

Ohno, 2013, Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts, J. Immunother. Cancer, 1, 21, 10.1186/2051-1426-1-21

Pegram, 2012, Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning, Blood, 119, 4133, 10.1182/blood-2011-12-400044

Pickup, 2013, The roles of TGFbeta in the tumour microenvironment, Nat. Rev. Cancer, 13, 788, 10.1038/nrc3603

Qasim, 2017, Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells, Sci. Transl. Med., 9, eaaj2013, 10.1126/scitranslmed.aaj2013

Qi, 2020, Chemically programmable and switchable CAR-T therapy, Angew. Chem. Int. Ed., 59, 12178, 10.1002/anie.202005432

Qin, 2018, Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22, Mol. Ther. Oncolytics, 11, 127, 10.1016/j.omto.2018.10.006

Quintarelli, 2020, Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia, Leukemia, 34, 1102, 10.1038/s41375-019-0613-7

Rabinovich, 2007, Immunosuppressive strategies that are mediated by tumor cells, Annu. Rev. Immunol., 25, 267, 10.1146/annurev.immunol.25.022106.141609

Rafiq, 2020, Engineering strategies to overcome the current roadblocks in CAR T cell therapy, Nat. Rev. Clin. Oncol., 17, 147, 10.1038/s41571-019-0297-y

Rafiq, 2018, Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo, Nat. Biotechnol., 36, 847, 10.1038/nbt.4195

Raj, 2019, Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma, Gut, 68, 1052, 10.1136/gutjnl-2018-316595

Reighard, 2020, Therapeutic targeting of follicular T Cells with chimeric antigen receptor-expressing natural killer cells, Cell Rep. Med., 1, 100003, 10.1016/j.xcrm.2020.100003

Ren, 2017, A versatile system for rapid multiplex genome-edited CAR T cell generation, Oncotarget, 8, 17002, 10.18632/oncotarget.15218

Ridge, 1998, A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell, Nature, 393, 474, 10.1038/30989

Rodgers, 2016, Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies, Proc. Natl. Acad. Sci. U S A, 113, E459, 10.1073/pnas.1524155113

Roth, 2020, Pooled knockin targeting for genome engineering of cellular immunotherapies, Cell, 181, 1, 10.1016/j.cell.2020.03.039

Roybal, 2016, Precision tumor recognition by T cells with combinatorial antigen-sensing circuits, Cell, 164, 770, 10.1016/j.cell.2016.01.011

Ruella, 2016, Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies, J. Clin. Invest., 126, 3814, 10.1172/JCI87366

Rupp, 2017, CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells, Sci. Rep., 7, 737, 10.1038/s41598-017-00462-8

Sadelain, 2017, Therapeutic T cell engineering, Nature, 545, 423, 10.1038/nature22395

Sasaki, 2010, miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy, J. Transl Med., 8, 17, 10.1186/1479-5876-8-17

Scharping, 2016, The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction, Immunity, 45, 374, 10.1016/j.immuni.2016.07.009

Serafini, 2004, Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease, Hum. Gene Ther., 15, 63, 10.1089/10430340460732463

Shalabi, 2018, Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma, Haematologica, 103, e215, 10.3324/haematol.2017.183459

Shin, 2012, Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models, Blood, 119, 5678, 10.1182/blood-2011-09-380519

Siska, 2016, Suppression of Glut1 and glucose metabolism by decreased Akt/mTORC1 signaling drives T cell impairment in B cell leukemia, J. Immunol., 197, 2532, 10.4049/jimmunol.1502464

Sommermeyer, 2016, Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo, Leukemia, 30, 492, 10.1038/leu.2015.247

Srivastava, 2019, Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting, Cancer Cell, 35, 489, 10.1016/j.ccell.2019.02.003

Stadtmauer, 2020, CRISPR-engineered T cells in patients with refractory cancer, Science, 367, eaba7365, 10.1126/science.aba7365

Stancovski, 1993, Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors, J. Immunol., 151, 6577, 10.4049/jimmunol.151.11.6577

Stephan, 2007, T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection, Nat. Med., 13, 1440, 10.1038/nm1676

Sterner, 2019, GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts, Blood, 133, 697, 10.1182/blood-2018-10-881722

Straathof, 2005, An inducible caspase 9 safety switch for T-cell therapy, Blood, 105, 4247, 10.1182/blood-2004-11-4564

Suarez, 2016, Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model, Oncotarget, 7, 34341, 10.18632/oncotarget.9114

Tan, 2020, Chimeric antigen receptor-T cells with cytokine neutralizing capacity, Blood Adv., 4, 1419, 10.1182/bloodadvances.2019001287

Torikai, 2012, A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR, Blood, 119, 5697, 10.1182/blood-2012-01-405365

Torikai, 2013, Toward eliminating HLA class I expression to generate universal cells from allogeneic donors, Blood, 122, 1341, 10.1182/blood-2013-03-478255

Tormoen, 2018, Role of the immunosuppressive microenvironment in immunotherapy, Adv. Radiat. Oncol., 3, 520, 10.1016/j.adro.2018.08.018

Tran, 2013, Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia, J. Exp. Med., 210, 1125, 10.1084/jem.20130110

Valton, 2015, A multidrug-resistant engineered CAR T cell for allogeneic combination immunotherapy, Mol. Ther., 23, 1507, 10.1038/mt.2015.104

Vodnala, 2019, T cell stemness and dysfunction in tumors are triggered by a common mechanism, Science, 363, eaau0135, 10.1126/science.aau0135

Wang, 2006, Prostaglandins and cancer, Gut, 55, 115, 10.1136/gut.2004.047100

Wang, 2011, A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells, Blood, 118, 1255, 10.1182/blood-2011-02-337360

Weber, 2020, Transient “rest” induces functional reinvigoration and epigenetic remodeling in exhausted CAR-T cells, bioRxiv

Weber, 2019, Pharmacologic control of CAR-T cell function using dasatinib, Blood Adv., 3, 711, 10.1182/bloodadvances.2018028720

Wei, 2019, Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy, Nature, 576, 471, 10.1038/s41586-019-1821-z

Weinberg, 2019, Reactive oxygen species in the tumor microenvironment: an overview, Cancers (Basel), 11, 1191, 10.3390/cancers11081191

Whiteside, 2008, The tumor microenvironment and its role in promoting tumor growth, Oncogene, 27, 5904, 10.1038/onc.2008.271

Wiesinger, 2019, Clinical-scale production of CAR-T cells for the treatment of melanoma patients by mRNA transfection of a CSPG4-specific CAR under full GMP compliance, Cancers (Basel), 11, 1198, 10.3390/cancers11081198

Wilkie, 2012, Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling, J. Clin. Immunol., 32, 1059, 10.1007/s10875-012-9689-9

Yang, 2016, Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism, Nature, 531, 651, 10.1038/nature17412

Yeku, 2017, Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment, Sci. Rep., 7, 10541, 10.1038/s41598-017-10940-8

Zah, 2020, Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma, Nat. Commun., 11, 2283, 10.1038/s41467-020-16160-5

Zhang, 2011, Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment, Mol. Ther., 19, 751, 10.1038/mt.2010.313

Zhang, 2017, CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells, Front. Med., 11, 554, 10.1007/s11684-017-0543-6

Zhao, 2015, Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells, Cancer Cell, 28, 415, 10.1016/j.ccell.2015.09.004